Novocure (NVCR) Reports Phase 3 METIS Trial Met Primary Endpoint

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. CRWV

Go back to Novocure (NVCR) Reports Phase 3 METIS Trial Met Primary Endpoint
(NASDAQ: NVCR) Delayed: 17.78 +0.07 (0.40%)
Previous Close $17.71    52 Week High $28.95 
Open $17.62    52 Week Low $5.95 
Day High $18.05    P/E N/A 
Day Low $17.25    EPS $0.00 
Volume 1,037,316